Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men

Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men

Authors

  • Vincenzo De Sanctis Quisisana Hospital, Ferrara
  • Ashraf T Soliman Department of Pediatrics, Hamad General Hospital, Doha, Qatar
  • Shahina Daar Department of Hematology, College of Medicine and Health Sciences Sultan Qaboos University Muscat, Sultanate of Oman
  • Salvatore Di Maio Emeritus Director in Pediatrics, Children's Hospital "Santobono-Pausilipon", Naples, Italy

Keywords:

Thalassemia major, Testosterone therapy, Adverse events, Gynecomastia, Priapism

Abstract

Background: Hormonal treatment of hypogonadism in thalassaemia major (TM) is a complex issue due to the co-existence of other contributing factors such as severity of iron overload, associated chronic liver disease and other endocrine complications. Objectives: Data about adverse events (AEs) of testosterone replacement therapy (TRT) in hypogonadal males with TM is scarce.We report the adverse events registered during TRT in 95 young patients with TM. Results: These AEs included gynecomastia, documented in 41/95 (43.1%) TM patients of mild to moderate severity (90%). Persistent pain in the injection site and local reactions to testosterone (T) skin patch occurred in a third of patients. Priapism was reported in 2 patients on treatment with intramuscular T enanthate. In both patients, substitution with T gel was successful, and no recurrence during the following 24 months was observed. Conclusions: Clinicians should exercise caution when considering TRT for hypogonadal men with TM. (www.actabiomedica.it)

Downloads

Published

23-05-2019

Issue

Section

ORIGINAL ARTICLES

How to Cite

1.
De Sanctis V, Soliman AT, Daar S, Di Maio S. Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men. Acta Biomed [Internet]. 2019 May 23 [cited 2024 Jul. 20];90(2):228-32. Available from: https://www.mattioli1885journals.com/index.php/actabiomedica/article/view/8477